Created On: 2020-07-15
Record Count: 5
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 3281
HyStem kits are for culturing stem cells whose natural environments are rich in hyaluronic acid.
The Licensor now has a worldwide License for all uses, with the exception of veterinary medicine and animal health.
IPSCIO Record ID: 265251
We may only develop, sell, and otherwise commercialize a product under the Utah Sublicense and HyStem License if we spend at least a low seven figure amount on research with respect to the product. Licensor will agree to provide us with a reasonable amount of the hydrogel product for the purpose of our research for we will pay Licensorâ€™s cost of manufacturing and supplying the hydrogel.
IPSCIO Record ID: 25871
IPSCIO Record ID: 168
Company granted an exclusive license to use its â€œACTCellerateâ€ embryonic stem cell technology and a bank of over 140 diverse progenitor cell lines derived using that technology.
The licensed rights include pending patent applications, knowledge and the existing bank of cell lines. The licence is exclusive and worldwide for all commercial purposes, including the development of research products, and therapeutic and diagnostic products for human and veterinary use. Licensor has an option to reacquire rights to use the technology for the development of certain types of SCs for human therapeutic use in fields re-lated to its core business.
The technology allows the rapid isolation of novel, highly-purified embryonic progenitor cells. The progenitor cells are relatively easy to manufacture on a large scale and in a purified state, which may make it advantageous to work with these cells compared to the direct use of ESCs. These unique cell lines may have potential applications in research, drug discovery and human regenerative SC therapy.
103080-069-WO1 (PCT/US06/13519, filed on 4-11-06): Novel uses of cells with Prenatal Patterns of prenatal gene expression, published as WO2007/058671
103080-071-P61 (USSN 60/791,400, filed on Apr. 11, 2006): Methods to accelerate the isolation of novel cell strains from pluripotent ST
103080-071-P66 (USSN 60/850,294, filed on Oct. 6, 2006), Methods to accelerate the isolation ov novel cell strains from pluripotent stem cells
103080-071-P01 (USSN 11/604,047, filed on Nov. 21, 2006), Methods to accelerate the isolation of novel cell strains from pluripotent STE…
PCT is 103080-071-WO2 (PCT/US2006/45352, filed on Nov. 21, 2006), published as WO 2007/062198.
IPSCIO Record ID: 7236
â€¢human somatic cell nuclear transfer applications for therapeutic purposes and
â€¢the cloning of animals for agricultural purposes, for the production of recombinant proteins, peptides and polypeptides for human transplantation, cells for human transplantation and tissues from human transplantation, but excluding the Licensor's field.